New drug combo after transplant may keep myeloma at bay

This study tested whether giving two drugs—ixazomib and lenalidomide—in an alternating schedule after a stem cell transplant could safely delay the return of multiple myeloma. Thirty patients who had already received a transplant took part. The main goal was to check for side effects over two years, while also tracking how long the cancer stayed away.